Training Program on HIV Diversity and Drug Resistance-Enhancing Research Capacity

艾滋病毒多样性和增强耐药性研究能力培训计划

基本信息

项目摘要

DESCRIPTION (provided by applicant): The broad HIV-1 genetic diversity and the emergence of drug resistant variants in Cameroon adds to complicate the viral genetic diversity and poses potential problems for diagnosis and prevention efforts, requiring that the evolution of HIV-1 diversity be monitored, and that new HIV-1 variants be examined for sensitivity of detection by different HIV-1 test kits. These problems continue to underscore the need for further training and research in Cameroon. This training program entitled "Training Program on HIV Diversity and Drug Resistance: enhancing research capacity" is designed with long-term to build and strengthen research capacity at the Medical Diagnostic Center in Yaounde, Cameroon for conducting studies to 1) document and monitor HIV-1 genetic diversity and evolution; 2) document and monitor the emergence antiretroviral drug resistant HIV-1 variants; 3) study the biologic and immunologic properties of different HIV-1 variants including emerging and drug resistant strains; 4) monitor the ability of commercially available test kits to diagnose infection by caused by diverse HIV-1 strains; and 5) to improve quality assurance and laboratory biosafety. To achieve these objectives we will: a) Organize in-country training workshops that will provide short-term local onsite training on: i) quality assurance and laboratory biosafety; ii new technologies and commercially available test kits for the diagnosis of infections caused by diverse HIV strains; and iii) scientific and grant writing skills. b) Provide long-term training in New York for studies of molecular biology/epidemiology/biostatistics relevant to studies of HIV genetic diversity through non-degree or degree programs for pre- and post-doctoral fellows. c) Provide medium-term training in New York for fellows to perform hands-on-laboratory training on viral genetic subtype characterization and computational analysis to document and identify diverse HIV-1 strains and/or drug resistance mutations, and viral biologic and immunologic properties. d) Provide short-term training through hands-on-training in documenting drug resistance mutations and data interpretation, to attend courses on epidemiology and biostatistics and to work one-on-one with relevant mentors. And, e) To support in-country research by providing small grants to appropriate long-term "alumni" fellows to conduct studies that addresses the research goals of the MDC. This training program should build and strengthen the research capacity at MDC to conduct studies on HIV-1 diversity and drug resistance that are relevant to intervention and prevention programs in Cameroon.
描述(由申请人提供):喀麦隆广泛的HIV-1遗传多样性和耐药变体的出现使病毒遗传多样性复杂化,并为诊断和预防工作带来潜在问题,要求监测HIV-1多样性的演变,并检查不同HIV-1检测试剂盒检测新HIV-1变体的敏感性。这些问题继续强调需要在喀麦隆进行进一步的培训和研究。这一名为“艾滋病毒多样性和耐药性培训方案:加强研究能力”的培训方案旨在长期建设和加强喀麦隆雅温得医疗诊断中心的研究能力,以便开展以下研究:1)记录和监测艾滋病毒-1遗传多样性和进化;2)记录和监测出现的抗逆转录病毒耐药HIV-1变异;3)研究不同HIV-1变异(包括新发和耐药菌株)的生物学和免疫学特性;4)监测市售检测试剂盒诊断多种HIV-1毒株感染的能力;5)提高质量保证和实验室生物安全。为了实现这些目标,我们将:a)组织国内培训讲习班,提供短期的当地现场培训:i)质量保证和实验室生物安全;用于诊断各种艾滋病毒毒株引起的感染的新技术和市售检测试剂盒;iii)科学和拨款的写作技巧。b)提供长期的培训

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MIROSLAW K GORNY其他文献

MIROSLAW K GORNY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MIROSLAW K GORNY', 18)}}的其他基金

Protective role of V2 antibodies induced at mucosal tissues in macaques
猕猴粘膜组织中诱导的 V2 抗体的保护作用
  • 批准号:
    9187975
  • 财政年份:
    2015
  • 资助金额:
    $ 27.4万
  • 项目类别:
Monocional Antibody and Protein Core
单克隆抗体和蛋白核心
  • 批准号:
    8789435
  • 财政年份:
    2014
  • 资助金额:
    $ 27.4万
  • 项目类别:
Production of Cross-Neutralizing HIV-1 Antibodies from Single B Cells
从单个 B 细胞生产交叉中和 HIV-1 抗体
  • 批准号:
    8786133
  • 财政年份:
    2014
  • 资助金额:
    $ 27.4万
  • 项目类别:
Induction of HIV Neutralizing Antibodies by Targeting Macaque B Cell Receptors
通过靶向猕猴 B 细胞受体诱导 HIV 中和抗体
  • 批准号:
    8743681
  • 财政年份:
    2013
  • 资助金额:
    $ 27.4万
  • 项目类别:
Induction of HIV Neutralizing Antibodies by Targeting Macaque B Cell Receptors
通过靶向猕猴 B 细胞受体诱导 HIV 中和抗体
  • 批准号:
    8329172
  • 财政年份:
    2012
  • 资助金额:
    $ 27.4万
  • 项目类别:
Induction of HIV Neutralizing Antibodies by Targeting Macaque B Cell Receptors
通过靶向猕猴 B 细胞受体诱导 HIV 中和抗体
  • 批准号:
    8462899
  • 财政年份:
    2012
  • 资助金额:
    $ 27.4万
  • 项目类别:
Production of Cross-Neutralizing HIV-1 Antibodies from Single B Cells
从单个 B 细胞生产交叉中和 HIV-1 抗体
  • 批准号:
    8262818
  • 财政年份:
    2011
  • 资助金额:
    $ 27.4万
  • 项目类别:
VIRAL IMMUNOLOGY CORE
病毒免疫核心
  • 批准号:
    8134720
  • 财政年份:
    2010
  • 资助金额:
    $ 27.4万
  • 项目类别:
The Immunoglobulin Gene Usage for Anti-V3 Monoclonal Antibodies
抗 V3 单克隆抗体的免疫球蛋白基因用途
  • 批准号:
    8093754
  • 财政年份:
    2010
  • 资助金额:
    $ 27.4万
  • 项目类别:
Improving Research Capacity in Cameroon for Studies on HIV-Associated Malignancie
提高喀麦隆艾滋病毒相关恶性肿瘤的研究能力
  • 批准号:
    8309398
  • 财政年份:
    2010
  • 资助金额:
    $ 27.4万
  • 项目类别:

相似海外基金

Assessing the Clinical Utility of Proviral DNA-based Antiretroviral Drug Resistance Testing in Individuals Living with Human Immunodeficiency Virus Type 1
评估基于 Proviral DNA 的抗逆转录病毒耐药性检测在 1 型人类免疫缺陷病毒感染者中的临床效用
  • 批准号:
    449333
  • 财政年份:
    2020
  • 资助金额:
    $ 27.4万
  • 项目类别:
    Studentship Programs
Antiretroviral drug resistance in KwaZulu Natal
夸祖鲁纳塔尔省的抗逆转录病毒耐药性
  • 批准号:
    8545480
  • 财政年份:
    2013
  • 资助金额:
    $ 27.4万
  • 项目类别:
Antiretroviral drug resistance in KwaZulu Natal
夸祖鲁纳塔尔省的抗逆转录病毒耐药性
  • 批准号:
    8894367
  • 财政年份:
    2013
  • 资助金额:
    $ 27.4万
  • 项目类别:
Antiretroviral drug resistance in KwaZulu Natal
夸祖鲁纳塔尔省的抗逆转录病毒耐药性
  • 批准号:
    8709982
  • 财政年份:
    2013
  • 资助金额:
    $ 27.4万
  • 项目类别:
Antiretroviral drug resistance in KwaZulu Natal
夸祖鲁纳塔尔省的抗逆转录病毒耐药性
  • 批准号:
    9463184
  • 财政年份:
    2013
  • 资助金额:
    $ 27.4万
  • 项目类别:
ANTIRETROVIRAL DRUG RESISTANCE--CLINICAL AND IMMUNE EFFECTS
抗逆转录病毒耐药性——临床和免疫影响
  • 批准号:
    3791777
  • 财政年份:
  • 资助金额:
    $ 27.4万
  • 项目类别:
ANTIRETROVIRAL DRUG RESISTANCE--CLINICAL AND IMMUNE EFFECTS
抗逆转录病毒耐药性——临床和免疫影响
  • 批准号:
    3727424
  • 财政年份:
  • 资助金额:
    $ 27.4万
  • 项目类别:
ANTIRETROVIRAL DRUG RESISTANCE--CLINICAL AND IMMUNE EFFECTS
抗逆转录病毒耐药性——临床和免疫影响
  • 批准号:
    3747322
  • 财政年份:
  • 资助金额:
    $ 27.4万
  • 项目类别:
ANTIRETROVIRAL DRUG RESISTANCE--CLINICAL AND IMMUNE EFFECTS
抗逆转录病毒耐药性——临床和免疫影响
  • 批准号:
    3769657
  • 财政年份:
  • 资助金额:
    $ 27.4万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了